A Dose-finding Study of Silodosin in Patients With Urinary Calculi
Launched by KISSEI PHARMACEUTICAL CO., LTD. · Feb 24, 2012
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have a unilateral ureteral calculus with ≥ 5 mm and ≤ 10 mm at Week 0.
- • Patients who are able to visit the site continually as out-patient during the study
- Exclusion Criteria:
- • Patients who have multiple urethral stones.
- • Patients who have or have history of a ureteral stricture or other structural passage obstruction of the ureter on affected side.
- • Patients who have been diagnosed with myasthenia gravis, myopathy, spina bifida, spinal cord injury, or fibromyalgia syndrome.
- • Patients who have a clinically significant hepatic or renal disorder.
- • Patients with postural hypotension or with a history of postural hypotension.
- • Patients with a history of sever drug allergy, or patients with a history of hypersensitivity to silodosin.
- • Patients who are pregnant, nursing, or desire pregnancy during the study period, or patients who cannot strictly comply with a physician's contraception directions.
Trial Officials
Tatsuro Takei
Study Director
Clinical Development Department, Kissei pharmaceutical Co., Ltd.
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong focus on specialty pharmaceuticals, Kissei leverages advanced technologies and rigorous clinical research to create effective treatments in areas such as urology, nephrology, and diabetes management. Committed to enhancing patient outcomes, Kissei collaborates with healthcare professionals and research institutions worldwide, ensuring a comprehensive approach to drug development that aligns with global health standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo And Other Japanese City, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials